Company Overview and News

 
Housing finance firms come crashing down

2018-09-22 freepressjournal.in
Mumbai : Shares of housing finance companies took a massive beating on Friday, with Dewan Housing Finance (DHFL) tumbling up to 42 per cent on massive selling over fears of a liquidity crisis, which had a cascading effect on the broader market as well.
YESBANK EDELWEISS 511072 IDKQY 532737 CANFINHOME 532648 YYBKY 532922 511196 SRTRANSFIN 511218 535789 IBULHSGFIN DHFL EMKAY BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 3772 500253 500034

 
DHFL stock cracks 42%; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes, but managed to trim a bit of losses on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock cracks 60% to below Rs 300; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock halves to trade below Rs 400, other housing finance firms also follow suit

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged 42.5 percent to hit fresh 52-week low of Rs 351.05 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
Shriram Transport Finance recoups losses to rally 4% after management clarification on SVL case

2018-09-14 moneycontrol
Shriram Transport Finance Corporation share price fell nearly 4 percent in early trade but managed to recoup those losses to rally more than 4 percent intraday on Friday, after the management clarified on SVL case.
511218 532498 SHRIRAMCIT SRRQY SRTRANSFIN

 
Broker's Call: Shriram Transport (Buy)

2018-09-03 thehindubusinessline
Shriram Transport Finance has shown recovery in assests under management (AUM) since the last few quarters backed by strong CV demand in the country. Infrastructure development and recovery in rural economy has kept AUM growth stronger. IND-AS (Indian accounting standards) transition has been positive.
511218 SRRQY SRTRANSFIN

 
Fund raising via NCDs jumps to Rs 21,048 cr in April-July

2018-09-03 thehindubusinessline
As many as seven companies raised over Rs 21,000 crore through issuance of debentures during April-July period of the ongoing fiscal, a surge of nearly five times from the year-ago period.
511218 DHFL MUTHOOTFIN 511072 SRRQY 533398 SRTRANSFIN

 
Fund raising via NCDs rises 5 times to Rs 21,000 crore in Apr-Jul

2018-09-03 moneycontrol
As many as seven companies raised over Rs 21,000 crore through issuance of debentures during April-July period of the ongoing fiscal, a surge of nearly five times from the year-ago period.
511218 DHFL MUTHOOTFIN 511072 SRRQY 533398 SRTRANSFIN

 
Uday Kotak, Asia’s richest banker, may acquire rivals after RBI’s rebuff

2018-08-28 livemint
Mumbai: A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a $17 billion acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd. below 20 percent. Buying another financial firm may be the most palatable way for Kotak to pare his holding, following the Reserve Bank of India’s rejection earlier this month of a preference share sale proposal.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
Asia's richest banker may acquire rivals after RBI's rebuff

2018-08-28 malaymail
MUMBAI, Aug 28 — A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a US$17 billion (RM69.5 billion) acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd below 20 per cent.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
Asia's richest banker may acquire rivals after RBI's rebuff

2018-08-28 theedgemarkets
MUMBAI (Aug 28): A rebuff from the regulator may set Asia’s richest banker Uday Kotak on a US$17 billion acquisition trail, as he seeks to meet a year-end deadline to reduce his stake in Kotak Mahindra Bank Ltd below 20%.
511218 AXBKY AXBA AXB KMBKY AXISBANK SRRQY KOTAKBANK 500247 SRTRANSFIN 532215

 
An evening walk down Dalal Street | Global cues, banks and metals fuel rally on D-Street; Nifty ends just below 11,700

2018-08-27 moneycontrol
What a cracker of a Monday that was for the market! Bulls had it their way throughout the session, gaining with every passing hour. Benchmarks ended the day at record high levels. The Nifty managed to clock 11,700-mark as well.
500325 SUNDARMFIN 570002 RELIANCE FRL 532978 BHRQY SRTRANSFIN 511218 532454 BAJAJFINSV LICHSGFIN FRLDVR RIGD SRRQY 523574 LHFLY BHARTIARTL 590071 500253 RLNIY SNDMY

 
Shriram Transport up 4%; foreign brokerages maintain buy with target upto Rs 1,890

2018-08-27 moneycontrol
Shares of Shriram Transport Finance Corporation added 4.6 percent intraday Monday as foreign research house maintained buy on the stock with a target upto Rs 1,890 per share.
511218 SRRQY SRTRANSFIN

 
TPG leads $100 million funding in non-bank lender Five Star Business Finance

2018-07-31 livemint
Mumbai: Global alternative asset firm TPG said on Tuesday it has led a $100 million (Rs685 crore) investment round in non-bank lender Five Star Business Finance Ltd. The round also saw participation from existing investors Norwest Venture Partners, an investment fund managed by Morgan Stanley, and Sequoia Capital. Five Star’s first institutional investor, Matrix Partners, continues to stay invested in the company, TPG said.
UBNC SRTRANSFIN 511218 532498 SHRIRAMCIT SRRQY MS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...